Filing Details
- Accession Number:
- 0001181431-14-038231
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-12-05 18:43:13
- Reporting Period:
- 2014-12-03
- Filing Date:
- 2014-12-05
- Accepted Time:
- 2014-12-05 18:43:13
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1407038 | Bg Medicine Inc. | BGMD | In Vitro & In Vivo Diagnostic Substances (2835) | 043506204 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1097548 | Newcogen Group Llc | C/O Flagship Ventures One Memorial Drive, 7Th Floor Cambridge MA 02142 | No | No | Yes | No | |
1222012 | Noubar Afeyan | C/O Flagship Ventures One Memorial Drive, 7Th Floor Cambridge MA 02142 | Yes | No | Yes | No | |
1255927 | Jr M Edwin Kania | C/O Flagship Ventures One Memorial Drive, 7Th Floor Cambridge MA 02142 | No | No | Yes | No | |
1400240 | Flagship Ventures Management, Inc. | C/O Flagship Ventures One Memorial Drive, 7Th Floor Cambridge MA 02142 | No | No | Yes | No | |
1400241 | Newcogen Group, Inc. | C/O Flagship Ventures One Memorial Drive, 7Th Floor Cambridge MA 02142 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-12-03 | 17,080 | $0.02 | 2,451,880 | No | 4 | X | Indirect | Held by NewcoGen Group LLC |
Common Stock | Disposition | 2014-12-03 | 616 | $0.46 | 2,451,264 | No | 4 | S | Indirect | Held by NewcoGen Group LLC |
Common Stock | Acquisiton | 2014-12-03 | 17,080 | $0.02 | 2,468,344 | No | 4 | X | Indirect | Held by NewcoGen Group LLC |
Common Stock | Disposition | 2014-12-03 | 616 | $0.46 | 2,467,728 | No | 4 | S | Indirect | Held by NewcoGen Group LLC |
Common Stock | Acquisiton | 2014-12-03 | 17,080 | $0.02 | 2,484,808 | No | 4 | X | Indirect | Held by NewcoGen Group LLC |
Common Stock | Disposition | 2014-12-03 | 616 | $0.46 | 2,484,192 | No | 4 | S | Indirect | Held by NewcoGen Group LLC |
Common Stock | Disposition | 2014-12-04 | 2,484,192 | $0.00 | 0 | No | 4 | J | Indirect | Held by NewcoGen Group LLC |
Common Stock | Acquisiton | 2014-12-04 | 164,528 | $0.00 | 175,718 | No | 4 | J | Direct | |
Common Stock | Acquisiton | 2014-12-04 | 10,029 | $0.00 | 10,029 | No | 4 | J | Indirect | Held by Atlast LP |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | X | Indirect | Held by NewcoGen Group LLC |
No | 4 | S | Indirect | Held by NewcoGen Group LLC |
No | 4 | X | Indirect | Held by NewcoGen Group LLC |
No | 4 | S | Indirect | Held by NewcoGen Group LLC |
No | 4 | X | Indirect | Held by NewcoGen Group LLC |
No | 4 | S | Indirect | Held by NewcoGen Group LLC |
No | 4 | J | Indirect | Held by NewcoGen Group LLC |
No | 4 | J | Direct | |
No | 4 | J | Indirect | Held by Atlast LP |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Warrant to Purchase Common Stock (right to buy) | Disposition | 2014-12-03 | 17,080 | $0.00 | 17,080 | $0.02 |
Common Stock | Warrant to Purchase Common Stock (right to buy) | Disposition | 2014-12-03 | 17,080 | $0.00 | 17,080 | $0.02 |
Common Stock | Warrant to Purchase Common Stock (right to buy) | Disposition | 2014-12-03 | 17,080 | $0.00 | 17,080 | $0.02 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2020-03-30 | No | 4 | X | Indirect | |
0 | 2020-09-27 | No | 4 | X | Indirect | |
0 | 2020-11-04 | No | 4 | X | Indirect |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 215,013 | Indirect | Held by AGTC Advisors Fund, L.P. |
Common Stock | 2,851,447 | Indirect | Held by Applied Genomic Technology Capital Fund, L.P. |
Common Stock | 1,764,286 | Indirect | Held by Flagship Ventures Fund 2007, L.P. |
Footnotes
- NewcoGen Group, Inc. ("NG") is the manager of NewcoGen Group LLC ("NGG"). NG is also the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors Fund, L.P. ("AGTCA") and Applied Genomic Technology Capital Fund L.P. ("AGTCF", and together with AGTCA, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar Afeyan and Edwin M. Kania, Jr. are directors of Flagship and may be deemed to beneficially own the securities held by NGG and the AGTC Funds. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- On December 3, 2014, NGG exercised a warrant to purchase 17,080 shares of Common Stock for $0.02 per share. NGG exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 616 of the warrant shares to pay the exercise price and issuing to NGG the remaining 16,464 shares.
- The price reflects the average of the closing prices of the Common Stock over the five day period prior to the exercise date.
- On December 3, 2014, NGG exercised a warrant to purchase 17,080 shares of Common Stock for $0.02 per share. NGG exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 616 of the warrant shares to pay the exercise price and issuing to NGG the remaining 16,464 shares.
- On December 3, 2014, NGG exercised a warrant to purchase 17,080 shares of Common Stock for $0.02 per share. NGG exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 616 of the warrant shares to pay the exercise price and issuing to NGG the remaining 16,464 shares.
- In addition to the cashless exercises of the warrants reported above, this Form 4 is being filed to report a pro-rata distribution by NGG for no consideration to its members. As members of NGG, Noubar Afeyan received 164,528 shares of Common Stock and Atlast LP received 10,029 shares of Common Stock in the distribution. The beneficial ownership of the entities named in this Form 4, other than the Reporting Persons filing this Form 4, did not change as a result of this transaction.
- Noubar Afeyan is the general partner of Atlast LP and may be deemed to beneficially own the securities held by Atlast LP. Mr. Afeyan disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- Noubar Afeyan and Edwin M. Kania, Jr. are managers of Flagship Ventures 2007 General Partner, LLC, which is the general partner of Flagship Ventures Fund 2007, L.P., and may be deemed to beneficially own the securities held by Flagship Ventures Fund 2007, L.P. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- This warrant is immediately exercisable.